ClinicalTrials.Veeva

Find clinical trials for Melanoma in Milano, Lombardia

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Renal Cell Carcinoma
Lung Cancer
Squamous Cell Carcinoma

Melanoma trials near Milano, Lombardia, ITA:

Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma (NEO-TIM)

given in combination or sequence may have an anti-tumour activity and may reduce the risk of relapse in patients with high-risk resectable melanoma...

Active, not recruiting
Melanoma
Drug: Cobimetinib 20 MG Oral Tablet
Drug: Atezolizumab 1200 MG in 20 ML Injection

Phase 2

Fondazione Melanoma Onlus

Milano, Italy and 5 other locations

Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma...

Enrolling
Uveal Melanoma
Drug: Darovasertib

Phase 2

Ideaya Biosciences

Milano, Italy and 22 other locations

This study observes the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma...

Enrolling
Mucosal Melanoma
Cutaneous Melanoma
Drug: Nemvaleukin Alfa Intravenous Less Frequent Dosing
Drug: Nemvaleukin Alfa Intravenous

Phase 2

Mural Oncology, Inc

Milano, Italy and 40 other locations

the efficacy and safety of 12 months of encorafenib in combination with binimetinib in adjuvant setting of BRAF V600E/K mutant stage IIB/C melanoma...

Active, not recruiting
Melanoma
Drug: Placebo to match Encorafenib ; Placebo to match Binimetinib
Drug: Encorafenib and Binimetinib

Phase 3

Pierre Fabre
Pierre Fabre

Milano, Italy and 154 other locations

medicines (ipilimumab and nivolumab) given for the treatment of melanoma.Melanoma is a type of cancer that starts in the cells that...

Enrolling
Melanoma
Drug: encorafenib
Drug: ipilimumab

Phase 2

Pfizer
Pfizer

Milano, Italy and 62 other locations

therapy per local standard of care (SoC), best supportive care (BSC)) on protocol survivor follow up) in patients with advanced non-ocular melanoma...

Enrolling
Advanced Melanoma
Drug: Tebentafusp with Pembrolizumab
Drug: Tebentafusp

Phase 2, Phase 3

Immunocore
Immunocore

Milano, Italy and 70 other locations

Locations recently updated

(PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma...

Enrolling
Melanoma
Drug: EU-authorized Nivolumab
Drug: ABP 206

Phase 3

Amgen
Amgen

Milano, Italy and 105 other locations

binimetinib, and pembrolizumab) given together for the treatment of melanoma that:is advanced or metastatic (spread to other parts of the bo...

Active, not recruiting
Melanoma
Drug: Binimetinib
Drug: Encorafenib

Phase 3

Pfizer
Pfizer

Milano, Italy and 227 other locations

Locations recently updated

assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma...

Enrolling
Melanoma
Drug: Nivolumab
Drug: ABP 206

Phase 3

Amgen
Amgen

Milano, Italy and 84 other locations

This is a Phase 2 multicenter, open label, non-randomized, interventional study enrolling 53 patients.The objectives and purposes of the clinical stu...

Enrolling
Malignant Melanoma
Combination Product: Pembrolizumab

Phase 2

European Institute of Oncology

Milan, Italy

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems